New Delhi: Based on its recent analysis of the global decentralized clinical trials (DCT) industry, Frost & Sullivan has recognized leading global clinical research organization (CRO) Parexel with the 2022 Global Customer Value Leadership Award.
Parexel combines in-house expertise, patient and caregiver insights, and cutting-edge technologies to plan, operationalize, and deliver DCTs for biopharmaceutical customers worldwide while ensuring the highest levels of patient safety. The company offers Phase I-IV clinical trial capabilities, integrated consulting expertise, and broad therapeutic expertise to accelerate new therapies for patients.
Parexel has earned a reputation of supporting its customers’ path toward minimizing patient burden while accumulating real-time, accurate clinical trial data. It builds its DCT solutions by collaborating closely with a range of stakeholders and partners to evolve alongside market needs and trends. For example, Parexel’s Patient Innovation Center optimizes patient recruitment strategies, enhances patient retention, and increases patient engagement by ensuring trials incorporate patients’ perspectives as much as possible. This Patients-first approach covers three crucial phases of clinical trial planning and design:
Before every DCT study—Identify and address potential barriers that hinder participation and inclusion, including medical/scientific, logistical, and cultural/behavioral differences
During a DCT study—Assist patients with eConsent, home nursing, direct-to-patient drug shipments, and video-monitored dosing to simplify the process
Post-study—Promptly support customers with getting crucial therapies into the market and facilitating early access to medicines